Medtronic Plc 10-K Summary: Fiscal Year Ended April 24, 2026
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended April 24, 2026. Medtronic Plc is a leading global healthcare technology company headquartered in Galway, Ireland, with primary operations in the Minneapolis, Minnesota area. The company operates through three reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. A significant strategic development during the period was the separation of the Diabetes Business into a new independent public company, MiniMed Group, Inc. (MiniMed), which completed its initial public offering (IPO) on March 9, 2026. As of the filing date, Medtronic retains approximately 90% ownership of MiniMed, and the Diabetes Business is no longer presented as a separate reportable segment.
Key Financial Metrics
| Metric | Fiscal Year 2026 | Fiscal Year 2025 | Change |
|---|---|---|---|
| Total Net Sales | $36.36 billion | $33.54 billion | +8.4% |
| Net Income (GAAP) | $4.80 billion | $4.66 billion | +3.0% |
| Diluted EPS (GAAP) | $3.73 | $3.61 | +3.3% |
| Operating Cash Flow | $7.33 billion | $7.04 billion | +4.1% |
| Free Cash Flow | $5.43 billion | $5.19 billion | +4.6% |
| Total Debt | $28.0 billion | $28.5 billion | -1.8% |
| Cash & Cash Equivalents | $1.95 billion | $2.22 billion | -12.2% |
| Effective Tax Rate | 21.2% | 16.6% | +4.6 pts |
Segment Performance: Cardiovascular sales grew 12% to $14.0 billion; Neuroscience sales grew 4% to $10.3 billion; Medical Surgical sales grew 5% to $8.8 billion. The Diabetes Business (now MiniMed) reported sales of $3.1 billion, a 13% increase.
Material Changes vs. Prior Period
- Revenue Growth: Total net sales increased 8% year-over-year, driven by growth across most businesses, foreign currency fluctuations, and a $39 million favorable adjustment to Italian payback accruals (compared to a $90 million unfavorable adjustment in 2025).
- Cost Pressures: Cost of products sold increased as a percentage of net sales, primarily due to $185 million in increased tariffs and duties and $84 million in asset write-offs.
- Tax Rate Increase: The effective tax rate rose to 21.2% from 16.6%, attributed to the implementation of the OECD Pillar Two Global Minimum Tax, intercompany intellectual property transactions, and the separation of the Diabetes Business.
- MiniMed IPO: The company raised $538 million in proceeds from the MiniMed IPO. Medtronic retains a controlling interest, and the results remain consolidated.
- Acquisitions: Medtronic acquired CathWorks Ltd. for $525 million to expand its Coronary & Peripheral Vascular division. A subsequent event noted the acquisition of Scientia Vascular for approximately $550 million upfront plus contingent consideration.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects continued growth driven by innovation in AI, data analytics, and new product launches. However, the company anticipates pre-tax net tariff impacts of approximately $250 million in fiscal year 2027. The company is monitoring the U.S. Supreme Court ruling on tariff policies which may allow for refunds.
Key Risks and Contingencies:
- Cybersecurity Incident: On April 24, 2026, Medtronic announced an unauthorized third-party access to certain IT systems. The company states there is no impact to patient safety, products, or financial reporting systems, and does not currently expect a material financial impact.
- Legal Proceedings: A jury returned a verdict against Medtronic in an antitrust case (Applied Medical) awarding $382 million in damages (subject to trebling). Medtronic plans to appeal and has not recorded a liability as the outcome is uncertain. Other significant litigation includes hernia mesh and diabetes pump retainer ring cases.
- Regulatory Environment: The company faces ongoing challenges with the EU Medical Device Regulation (MDR) and potential reimbursement pressures in the U.S. and China.
- Geopolitical Factors: Conflicts in the Middle East and Russia-Ukraine continue to pose supply chain and cost risks, though the direct financial impact in fiscal 2026 was not material.
Investor Verification Checklist
- MiniMed Separation Timeline: Verify the timeline and terms for the divestiture of the remaining ~90% stake in MiniMed Group, Inc.
- Tariff Exposure: Assess the potential financial impact of the estimated $250 million tariff cost in fiscal 2027 and the status of refund claims following the U.S. Supreme Court ruling.
- Antitrust Litigation: Monitor the status of the Applied Medical antitrust appeal and the potential for a trebled damages award.
- Cybersecurity Follow-up: Review future disclosures regarding the April 2026 data breach to confirm no material impact on operations or reputation.
- Italian Payback Liability: Track ongoing discussions with the Italian government regarding payback legislation applicability for years 2019 and beyond.
- Debt Maturities: Review the schedule of debt maturities, noting significant repayments due in fiscal years 2027 through 2031.